CalciMedica Inc. (CALC)
3.01
-0.17 (-5.35%)
At close: Jan 15, 2025, 11:10 AM
Company Description
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs.
Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.
Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury.
The company is based in La Jolla, California.
CalciMedica Inc.
| Country | United States |
| IPO Date | Jun 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. A. Rachel Leheny Ph.D. |
Contact Details
Address: 505 Coast Boulevard South La Jolla, California United States | |
| Website | https://www.calcimedica.com |
Stock Details
| Ticker Symbol | CALC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534133 |
| CUSIP Number | 38942Q202 |
| ISIN Number | US38942Q2021 |
| Employer ID | 45-2120079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | Chief Executive Officer & Director |
| Michael J. Dunn M.B.A., MBA | President & Chief Operating Officer |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer |
| Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board |
| John M. Dunn J.D. | General Counsel |
| Raven D. Jaeger M.S. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 424B5 | Filing |
| Dec 13, 2024 | SCHEDULE 13G | Filing |
| Dec 06, 2024 | 4 | Filing |
| Nov 26, 2024 | SC 13D | Filing |
| Nov 15, 2024 | 3 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |